Nicholson rejoins Rothschild as MD of Arrowpoint Advisory London healthcare team

Rothschild & Co’s dedicated UK mid-market advisory team Arrowpoint Advisory has appointed Andrew Nicholson as managing director in its London healthcare team.

Nicholson (pictured) was previously responsible for leading US investment bank Baird’s European healthcare team. Prior to that, he spent 15 years as UK head of healthcare M&A at at KPMG.

He has extensive experience as an advisor across the healthcare space and a successful track record of advising entrepreneurs, company shareholders and private equity investors throughout Europe.

Hedley Goldberg, global head of healthcare at Rothschild & Co, said: ‘Rothschild & Co has ambitious plans to continue to grow its healthcare team and welcoming Andrew back into the team is both a real pleasure and an important step in further expanding our coverage of the healthcare mid-market. As a healthcare advisor for 25 years and an alumnus of the Rothschild & Co team, Andrew brings both strong experience and connectivity in the market along with internal relationships across the firm to help deliver the best of Rothschild & Co to current and future clients.’

Karen Dawaf, managing director of Arrowpoint Advisory, added: ‘I’m delighted to welcome Andrew Nicholson to the mid-market Healthcare team. His expertise and experience will be invaluable as we continue to scale our platform in Healthcare and build on the strong growth we’ve seen across the sector. With multiple exciting opportunities ahead, we’re committed to investing behind this momentum and driving meaningful impact for our clients.’

Commenting on his appointment, Nicholson said: ;As a Rothschild & Co alumnus the offer to return and work closely with Hedley, Karen, Dustin and the wider team to build out Rothschild & Co’s mid-market healthcare presence was too exciting an opportunity to turn down. I’m really looking forward to working with investors, management teams and advisors across the UK market to bring the truly incredible amount of insight within Rothschild & Co to benefit clients in UK healthcare transactions in the months ahead.’